Features of integrin subunit β4 expression depending on clinical and morphological parameters of breast cancer
M. V. Zavyalova,
G. A. Kuznetsov,
E. S. Grigorieva,
L. A. Tashireva,
A. V. Zavyalov,
V. E. Popova,
V. V. Alifanov,
D. S. Pismenny,
E. S. Andryukhova,
V. M. Perelmuter https://doi.org/10.20538/1682-0363-2025-1-22-28
Abstract
Aim. To study the features of the expression of the integrin subunit β4 in primary tumor tissue depending on the clinical and morphological parameters of breast cancer.
Materials and methods. We examined biopsy samples from 49 patients with T1–4N0–3M0 breast cancer; the median age was 51.0 [44.0; 60.0] years. Patients did not receive neoadjuvant therapy. Surgical intervention involved resection of the mammary gland with axillary lymph node dissection or radical mastectomy. The expression of markers of estrogen receptor, progesterone receptor, c-erB-2 (Her2/neu), Ki67, CD104 (integrin subunit β4) was assessed using immunohistochemistry. Statistical processing of the results was carried out using the Statisctica 10.0 software package.
Results. In the group of patients with N3 degree, cases with positive cytoplasmic/membrane colocalization of integrin subunit β4 expression were more frequently detected (45%), compared with observations where no such expression was found (8%; p = 0.002).
Conclusion. Positive cytoplasmic/membrane colocalization of integrin subunit β4 expression is associated with the prevalence of lymphatic metastasis, which corresponds to N3 degree.
About the Authors
M. V. Zavyalova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences;
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009;
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
G. A. Kuznetsov
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
E. S. Grigorieva
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
L. A. Tashireva
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
A. V. Zavyalov
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
V. E. Popova
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
V. V. Alifanov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
D. S. Pismenny
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences;
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009;
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
E. S. Andryukhova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences;
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009;
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
V. M. Perelmuter
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Lane, Tomsk, 634009
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
References
1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022:239.
2. Berghof A.S., Kovanda A.K., Melchardt T., Bartsch R., Hainfellner J.A., Sipos B. et al. αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clin. Exp. Metastasis. 2014;31(7):841–851. DOI: 10.1007/s10585-014-9675-0.
3. Hoshino A., Costa-Silva B., Shen T.L., Rodrigues G., Hashimoto A., Tesic Mark M. et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–335. DOI: 10.1038/nature15756.
4. Gradishar W.J., Anderson B.O., Abraham J., Aft R., Agnese D., Allison K.H. et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2020;18(4):452–478. DOI: 10.6004/jnccn.2020.0016.
5. Bagati A., Kumar S., Jiang P., Pyrdol J., Zou A.E., Godicelj A. et al. Integrin αvβ6–TGFβ–SOX4 pathway drives immune evasion in triple-negative breast cancer. Cancer Cell. 2021;39(1):54–67.e9. DOI: 10.1016/j.ccell.2020.12.001.
6. Cooper J., Giancotti F.G. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35(3):347–367. DOI: 10.1016/j.ccell.2019.01.007.
7. Zahir N., Lakins J.N., Russell A., Ming W., Chatterjee C., Rozenberg G.I. et al. Autocrine laminin-5 ligates α6β4 integrin and activates RAC and NFκB to mediate anchorage-independent survival of mammary tumors. J. Cell. Biol. 2003;163(6):1397–1407. DOI:10.1083/jcb.200302023.
8. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010;10(1):9–22. DOI: 10.1038/nrc2748.
9. Stewart R.L., O’Connor K.L. Clinical significance of the integrin α6β4 in human malignancies. Lab. Invest. 2015;95(9):976–986. DOI: 10.1038/labinvest.2015.82.
10. Kim Y.N., Koo K.H., Sung J.Y., Yun U.J., Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int. J. Cell. Biol. 2012;(1):306879. DOI: 10.1155/2012/306879.
11. Pan L., Zhao Y., Yuan Z., Qin G. Research advances on structure and biological functions of integrins. Springerplus. 2016;5(1):1–11. DOI: 10.1186/s40064-016-2502-0.
12. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell. Biol. 2001;13(5):555–562. DOI: 10.1016/s0955-0674(00)00251-9.
13. Bertotti A., Comoglio P.M., Trusolino L. β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell. Biol. 2006;175(6):993–1003. DOI: 10.1083/jcb.200605114.
14. Ramovs V., Te Molder L., Sonnenberg A. The opposing roles of laminin-binding integrins in cancer. Matrix Biol. 2017;57:213–243. DOI: 10.1016/j.matbio.2016.08.007.
15. Воронина Е.И., Агеева Т.А., Рыжова М.В. Особенности микроокружения и возможности иммунотерапии злокачественных глиальных опухолей. Клиническая и экспериментальная морфология. 2020;9(2):5–10. DOI: 10.31088/CEM2020.9.2.5-10.
Review
For citations:
Zavyalova M.V., Kuznetsov G.A., Grigorieva E.S., Tashireva L.A., Zavyalov A.V., Popova V.E., Alifanov V.V., Pismenny D.S., Andryukhova E.S., Perelmuter V.M. Features of integrin subunit β4 expression depending on clinical and morphological parameters of breast cancer. Bulletin of Siberian Medicine. 2025;24(1):22-28. https://doi.org/10.20538/1682-0363-2025-1-22-28
Views:
300
Email this article 